MoonLake Immunotherapeutics announced Week 52 results from its Phase 3 VELA trials showing sonelokimab significantly improves symptoms in adults with moderate-to-severe hidradenitis suppurativa (HS), with 67% achieving HiSCR75 and 26% reaching inflammatory remission. The treatment also improved quality of life and reduced pain, with no new safety concerns. Positive interim results in adolescents were reported, and a Biologics License Application is planned for submission to the FDA by September 2026. An Investor Day webcast is scheduled for June 22, 2026, to discuss these results and upcoming milestones.
Lululemon invested in Syntetica's $30 million Series A funding to support its innovative recycling of Nylon 6 and Nylon 6,6, materials difficult to separate and reuse in textile waste. This move aligns with growing industry demand for sustainable, co...
Ethereum futures long positions among top traders increased by over 3 percentage points across both USDT- and coin-margined markets, indicating a broad-based shift in short-term sentiment. This rise suggests heightened attention on ETH compared to ot...
NVIDIA announced that leading Japanese companies in robotics and manufacturing are adopting its Cosmos, Isaac, Metropolis, and Jetson platforms to accelerate AI-powered intelligent machines across industries. The new Cosmos 3 Edge model enables real-...
Oil prices are rising sharply due to renewed US naval blockades on Iranian shipping and increased tensions in the Strait of Hormuz, a critical oil transit route. Brent crude is holding above $85 and WTI above $80, with forecasts suggesting WTI could ...
The US government announced it will impose a new 25% tariff on Brazilian ethanol starting next Wednesday, accusing Brazil of unfair trade practices. This tariff excludes major Brazilian exports like oil, beef, coffee, and aircraft parts. The move fol...
